DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Amgen Inc.

AMGNNASDAQ$439.26−$8.02 (−1.79%)Market closed

Price Chart

Daily

Key facts

Market Cap
$237.20B
P/E
30.6x
P/B
27.30x
ROE
106.1%

Amgen Inc.

Healthcare · Drug Manufacturers - General · FY 2025

Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.

CEO
Mr. Robert A. Bradway
Employees
28,000
Website
amgen.com

Company Statistics

Valuation

P/E
30.6x
P/B
27.30x
P/S
6.43x
EV/EBITDA
16.7x
P/FCF
29.2x

Margins

Gross
67.2%
EBITDA
46.0%
Operating
24.7%
Pre-Tax
24.4%
Net
21.0%

Returns

ROA
8.5%
ROE
106.1%
ROIC
12.9%

Growth (CAGR)

Rev 3Yr
11.8%
Rev 5Yr
7.6%
Op Inc 3Yr
−1.7%
Net Inc 3Yr
5.6%

Financial Health

Cash & Cash Equivalents
$9.13B
Net Debt
$72.80B
Debt/Equity
946.3%
Interest Cov
—

Profile

Revenue
$36.75B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Amgen Inc. (AMGN) Stock Forecast 2026 $439.26 — Price, Financials & Analyst Targets | AlphaLenz